BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

November 18, 2026 12:00 PM IST

- Transaction provides non-dilutive capital through sale of BioLineRx's portion of future APHEXDA royalties -

- Funds to support clinical development of GLIX1, including ongoing Phase 1/2a clinical trial, which is currently enrolling the fourth of five planned dosing cohorts -

- BioLineRx retains rights to future commercial milestone payments under its existing license agreement with Ayrmid -

TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- **BioLineRx Ltd.** (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into an agreement for the sale of its rights to certain future royalty payments from APHEXDA® (motixafortide) to Soleus Capital Management, L.P. and its affiliates ("Soleus") for a one-time payment of $5.6 million.

Under the terms of the agreement, Soleus will acquire BioLineRx's 14.4% royalty interest in future net sales of APHEXDA under the Company's existing license agreement with Ayrmid Pharma Ltd. ("Ayrmid"). The transaction excludes the remaining 3.6% royalty interest attributable to the original licensor of motixafortide to BioLineRx, which will continue to retain its interest in the royalty stream. BioLineRx has retained its rights to receive potential commercial milestone payments under the Ayrmid agreement, as well as royalty payments attributable to periods prior to the closing of the transaction.

"This transaction enables us to immediately unlock the value of our APHEXDA royalty stream and strengthen our financial position while retaining the potential for future commercial milestone payments," said Philip Serlin, Chief Executive Officer of BioLineRx. "Importantly, the non-dilutive capital will provide additional financial flexibility as we continue to advance our lead development asset, GLIX1, through its ongoing Phase 1/2a clinical trial in glioblastoma and other solid tumors. We believe this transaction represents an attractive, non-dilutive financing solution for our company and our shareholders."

"We are pleased to partner with BioLineRx on this transaction, which provides us with an opportunity to participate in the future commercial performance of APHEXDA," said Benjamin Lund, Partner at Soleus Capital. "We believe APHEXDA represents a differentiated treatment option in stem cell mobilization for patients with multiple myeloma, and we look forward to supporting BioLineRx through this innovative financing arrangement."

BioLineRx intends to use the proceeds to support its ongoing research and development activities, including the clinical development of GLIX1, as well as for working capital and general corporate purposes, including a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with the partial loan repayment, the Company's minimum cash balance requirement under the loan agreement (currently $4 million) will be eliminated. The transaction is expected to close on or about November 30, 2026.

About APHEXDA® (motixafortide)
APHEXDA is a CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplantation in patients with multiple myeloma. APHEXDA is being commercialized by Ayrmid globally, except in Asia, where it is partnered with Gloria Biosciences.

About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.

About Soleus Capital
Soleus Capital is an investment firm based in Greenwich, CT focused on the innovative areas of life sciences, including biopharmaceuticals, medical technologies, life sciences tools and diagnostics. With approximately $3.5 billion in total assets under management as of June 30, 2026, Soleus Capital invests across the healthcare lifecycle from developmental-stage through commercial, and partners with life science companies across the capital structure with hedge fund, private equity and structured credit vehicles.

Forward Looking Statement
Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects,"

"intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the consummation and expected benefits of the royalty monetization transaction with Soleus Capital; BioLine's receipt and intended use of the transaction proceeds; the completion and expected effects of the partial repayment of BioLine's outstanding loan facility, including the elimination of the minimum cash balance requirement; the future commercial performance, market uptake and net sales of APHEXDA; potential future royalty and commercial milestone payments relating to APHEXDA; the ongoing Phase 1/2a clinical trial of GLIX1, including its enrollment, progress and the timing and results of any clinical readout; and BioLineRx's business strategy, financial position and financing requirements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of GLIX1 and motixafortide including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance GLIX1 and motixafortide into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for GLIX1 and motixafortide will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for GLIX1 and motixafortide and the timing of other regulatory filings and approvals; whether access to GLIX1 and motixafortide is achieved in a commercially viable manner and whether GLIX1 and motixafortide receive adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel, as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection that BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its need for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; statements as to the impact of the political and security situation in Israel on BioLineRx's business which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2026. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contacts:

For BioLineRx:
United States
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolinerx-enters-into-5-6-million-royalty-monetization-transaction-with-soleus-capital-302943737.html

SOURCE BioLineRx Ltd.